Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares stood at 0.49 million during the last session, with the company’s beta value hitting 2.49. At the close of trading, the stock’s price was $2.46, to imply a decrease of -2.38% or -$0.06 in intraday trading. The BDTX share’s 52-week high remains $7.66, putting it -211.38% down since that peak but still an impressive 22.36% since price per share fell to its 52-week low of $1.91. The company has a valuation of $139.20M, with an average of 0.67 million shares in intraday trading volume over the past 10 days and average of 768.98K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Black Diamond Therapeutics Inc (BDTX), translating to a mean rating of 1.14. Of 3 analyst(s) looking at the stock, 0 analyst(s) give BDTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.31.
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
After registering a -2.38% downside in the last session, Black Diamond Therapeutics Inc (BDTX) has traded red over the past five days. The 5-day price performance for the stock is -6.11%, and 16.04% over 30 days. With these gigs, the year-to-date price performance is 14.95%. Short interest in Black Diamond Therapeutics Inc (NASDAQ:BDTX) saw shorts transact 7.49 million shares and set a 6.59 days time to cover.
The extremes give us $11 and $20 for target low and target high price respectively. As such, BDTX has been trading -713.01% off suggested target high and -347.15% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -49.79% for the past 5-year period. While 2025 is set for a 30.85% return in earnings, projections for the next 5 years are at 7.01% annually.
BDTX Dividends
Black Diamond Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
Black Diamond Therapeutics Inc insiders hold 2.75% of total outstanding shares, with institutional holders owning 98.82% of the shares at 101.61% float percentage. In total, 98.82% institutions holds shares in the company, led by T. ROWE PRICE INVESTMENT MANAGEMENT, INC.. As of 2024-06-30, the company held over 10.66 million shares (or 20.5751% of shares), all amounting to roughly $49.67 million.
The next major institution holding the largest number of shares is BELLEVUE GROUP AG with 8.52 million shares, or about 16.4409% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $39.69 million.
We also have Price (T.Rowe) Small-Cap Value Fund and Price (T.Rowe) Small Cap Stock Fund as the top two Mutual Funds with the largest holdings of the Black Diamond Therapeutics Inc (BDTX) shares. Going by data provided on Sep 30, 2024 , Price (T.Rowe) Small-Cap Value Fund holds roughly 2.56 shares. This is just over 4.53% of the total shares, with a market valuation of $6.3 million. Data from the same date shows that the other fund manager holds a little less at 2.51, or 4.43% of the shares, all valued at about 6.17 million.
